[go: up one dir, main page]

Chen et al., 2024 - Google Patents

Nanoparticles Fueled by Enzyme for the Treatment of Hyperlipidemic Acute Pancreatitis

Chen et al., 2024

Document ID
309715727890852417
Author
Chen G
Huang Y
Yu H
Wang J
Li H
Shen S
Zhou X
Shi K
Sun H
Publication year
Publication venue
ACS Biomaterials Science & Engineering

External Links

Snippet

Hyperlipidemic acute pancreatitis (HAP) is a serious inflammatory pancreatic disease commonly seen in patients with disorders of lipid metabolism. Decreasing blood triglyceride levels and proinflammatory factors can alleviate hyperlipidemic pancreatitis. The lipase that …
Continue reading at pubs.acs.org (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A61K47/48853—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48007—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48169—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/543—Immunoassay; Biospecific binding assay with an insoluble carrier for immobilising immunochemicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids

Similar Documents

Publication Publication Date Title
Pang et al. Detoxification of organophosphate poisoning using nanoparticle bioscavengers
Chen et al. Cell-membrane-cloaked oil nanosponges enable dual-modal detoxification
Villegas et al. Nanotechnological strategies for protein delivery
Ke et al. A decade of the protein corona
Xu et al. Molecularly imprinted polymer nanoparticles as potential synthetic antibodies for immunoprotection against HIV
Ruehle et al. A pathogen-specific cargo delivery platform based on mesoporous silica nanoparticles
Treuel et al. Impact of protein modification on the protein corona on nanoparticles and nanoparticle–cell interactions
Yang et al. Tumor‐specific peroxynitrite overproduction disrupts metabolic homeostasis for sensitizing melanoma immunotherapy
Totten et al. PEGylation-dependent metabolic rewiring of macrophages with silk fibroin nanoparticles
Ortac et al. Dual-porosity hollow nanoparticles for the immunoprotection and delivery of nonhuman enzymes
Rao et al. Tunable intracellular degradable periodic mesoporous organosilica hybrid nanoparticles for doxorubicin drug delivery in cancer cells
Forster et al. Nano-antidotes for drug overdose and poisoning
Duan et al. Capsulated cellular nanosponges for the treatment of experimental inflammatory bowel disease
Xiong et al. Nanosomal microassemblies for highly efficient and safe delivery of therapeutic enzymes
Wen et al. High-throughput colorimetric analysis of nanoparticle–protein interactions based on the enzyme-mimic properties of nanoparticles
Dogan et al. Leveraging affinity interactions to prolong drug delivery of protein therapeutics
Zhang et al. In situ construction of ferrocene-containing membrane-bound nanofibers for the redox control of cancer cell death and cancer therapy
Wong et al. Shielded α-nucleophile nanoreactor for topical decontamination of reactive organophosphate
Veiseh et al. In vivo safety evaluation of polyarginine coated magnetic nanovectors
Mirzazadeh Dizaji et al. Biomimetic mineralization of iron-fumarate nanoparticles for protective encapsulation and intracellular delivery of proteins
Szilasi et al. Nanoencapsulated and microencapsulated enzymes in drug antidotal therapy
Piacenza et al. Impact of biogenic and Chemogenic selenium nanoparticles on model eukaryotic lipid membranes
Lei et al. A Two-Pronged Nanostrategy of Iron Metabolism Disruption to Synergize Tumor Therapy by Triggering the Paraptosis–Apoptosis Hybrid Pathway
Ashkarran et al. Protein corona composition of gold nanocatalysts
Chen et al. Nanoparticles Fueled by Enzyme for the Treatment of Hyperlipidemic Acute Pancreatitis